BioSyent (CVE:RX) Sets New 12-Month High - Here's Why

Key Points

• BioSyent Inc.'s stock reached a new 52-week high, trading at C$12.49 before closing at C$12.00, with a market cap of C$135.13 million.
• The company announced a quarterly dividend of $0.05 per share, representing an annualized dividend of $0.20 and a yield of 1.7%, with a payout ratio of 26.76%.
• BioSyent, which focuses on pharmaceuticals and healthcare products, has notable offerings aimed at treating and preventing iron deficiency anemia.

BioSyent Inc. (CVE:RX - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as C$12.49 and last traded at C$12.00, with a volume of 2923 shares. The stock had previously closed at C$12.07.

BioSyent Trading Down 1.7%

The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90. The stock has a market capitalization of C$133.22 million, a P/E ratio of 16.66 and a beta of 0.49. The business's fifty day simple moving average is C$11.65 and its two-hundred day simple moving average is C$11.31.

BioSyent Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, September 15th. Stockholders of record on Friday, August 29th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 1.7%. BioSyent's payout ratio is presently 26.76%.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.